Bulk Pharmaceutical API Sources for KRAZATI

Bulk Pharmaceutical API Sources for KRAZATI

Vendor	Vendor Homepage	Vendor Sku	API Url
DC Chemicals		MRTX849
MedChemexpress MCE		HY-130149
AbaChemScene		CS-0105265

Bulk API Sources for KRAZATI (Rituximab)

Last updated: February 20, 2026

What are the primary sources for bulk active pharmaceutical ingredients (APIs) of KRAZATI?

KRAZATI (rituximab) is a monoclonal antibody (mAb) used to treat various hematological and autoimmune diseases. It is produced via complex biotechnological processes involving mammalian cell culture, typically Chinese Hamster Ovary (CHO) cells.

Bulk API sourcing for rituximab involves licensed manufacturers with facilities adhering to current Good Manufacturing Practice (cGMP) standards. There are three main categories of sources:

• Original (Innovator) API Suppliers
• Authorized Generics or Biosimilar Developers
• Contract Manufacturing Organizations (CMOs)

Who are the approved primary suppliers of rituximab API?

Innovator API Suppliers

The original rituximab API was developed by Roche, which also markets KRAZATI. Roche’s manufacturing facilities are compliant with global regulatory standards, including FDA (USA), EMA (Europe), and PMDA (Japan). Roche's API is usually obtained directly through their supply chain, primarily for proprietary use or licensed production.

Biotech and Biosimilar Manufacturers

Following patent expiry, biosimilar developers have entered the market. These companies have obtained licenses or have developed APIs for regulatory approval:

• Celltrion: Produces CT-P10, a biosimilar rituximab, with API manufacturing plants in South Korea.
• Sandoz (Novartis): Biosimilar rituximab with API sourced from their GMP-compliant facilities.
• Mabxience: An Argentine company producing biosimilar rituximab, with API manufacturing in Argentina.
• AryoGen Pharm: In Iran, producing rituximab biosimilar APIs.

Contract Manufacturing Organizations

CMOs that manufacture rituximab API generally work under licensing agreements with patent holders or biosimilar companies. Notable CMOs include:

• Samsung Biologics: Offers API production for biosimilars.
• Boehringer Ingelheim: Provides antibody manufacturing services, including rituximab.

What are the characteristics of these API sources?

Source Type	Examples	Manufacturing Locations	Certifications	Regulatory Standing
Innovator (Original) API	Roche	Switzerland, US	cGMP, FDA-inspected, EMA-approved	Fully licensed for proprietary supply
Biosimilar API developers	Celltrion, Sandoz	South Korea, Europe, Argentina	cGMP, EMA, FDA approvals	Approved or in approval processes; licensing necessary
Contract Manufacturing Organizations	Samsung Biologics	South Korea	cGMP, ISO certifications	Provides APIs under licensing; regulatory compliance varies

How does supply chain differ between sources?

• Original API: Limited to Roche or licensed partners; high cost; tight control.
• Biosimilars: Entry at different markets; lower cost; require regulatory approval.
• CMOs: Serve as manufacturing intermediaries; dependent on licensing agreements; supply often comes through licensed biosimilar or innovator companies.

Are there regional or legal considerations?

• Patent expiration impacts biosimilar market entry; patents for rituximab expired globally between 2018 and 2020.
• Regional regulatory approvals vary: the FDA and EMA approve biosimilar APIs; some countries require local approval.
• Supply chain security varies; active due diligence necessary to validate GMP compliance, especially for biosimilar sources.

What are the risks associated with sourcing API for KRAZATI?

• Regulatory compliance: Non-approved sources present legal and quality risks.
• Quality consistency: Variability in biosimilar API batches.
• Intellectual property: Licensing restrictions dictate authorized use.
• Supply stability: Limited manufacturing capacity or geopolitical issues can cause shortages.

Key Takeaways

• Original API from Roche dominates for proprietary production.
• Biosimilar APIs are increasingly available from manufacturers like Celltrion and Sandoz.
• CMOs supply APIs based on licensing agreements; quality depends on GMP compliance.
• Regional approval and patent status heavily influence API sourcing options.
• Quality, regulatory approval, and supply security are critical factors in decision-making.

FAQs

1. Who are the main manufacturers of rituximab API?
Roche (original API), Celltrion, Sandoz, Mabxience (biosimilars), and contract manufacturers like Samsung Biologics are primary sources.

2. Can biosimilar APIs be used interchangeably with original APIs?
Not necessarily; biosimilar APIs require regulatory approval and must meet strict biosimilarity criteria before use.

3. How do patent expirations impact API sourcing?
Patent expirations in 2018-2020 have enabled biosimilar developers to produce rituximab APIs legally in various jurisdictions.

4. What regulatory bodies approve rituximab APIs?
FDA, EMA, PMDA, and local health authorities approve biosimilar APIs within their jurisdictions.

5. Are there risks using APIs from CMOs?
Yes, risks include quality variability and supply disruptions; verifying GMP compliance is essential.

---

References

[1] U.S. Food and Drug Administration. (2022). Rituximab product approval information.
[2] European Medicines Agency. (2023). Biosimilar medicines.
[3] World Health Organization. (2021). Biosimilar medicines: overview of regulatory landscape.
[4] Roche. (2022). Rituximab API manufacturing details.
[5] Celltrion. (2022). Biosimilar rituximab API production.